Tuberculosis (TB) is among the world's top public health challenges and the leading killer of people with HIV, yet is a treatable disease. Over the past number of years, a large amount of evidence has been gathered about the negative impact of HIV on TB control. The HIV infection has markedly increased morbidity and mortality of Tuberculosis. Similarly, interventions to improve HIV-associated TB care have been found, and these form important components of the international standard of care for TB. In this book, we assess, in a real-world setting, the implementation of antiretroviral therapy (ART) and Cotrimoxazole preventive therapy (CPT) policy, specific interventions proven to benefit patients with HIV-associated TB care. We strongly believe that the analysis in this book will contribute to inform appropriate policy and patient care in this country and provide insight to clinicians and researchers in the field of HIV-associated Tuberculosis.